Septerna is developing drugs against G-protein coupled receptors (GPCRs). GPCRs are found at the cell membrane and have proven to be the most ‘druggable’ class of proteins. However, many remain ‘undruggable’. Septerna is addressing this problem using their Native Complex platform to design a new era of GPCR-targeted medicines. The platform recapitulates the native structure, function and dynamics of GPCRs, thus enabling structure-based drug design and large-scale screening. Drug hits are further examined with Cryo-EM and optimized through in silico approaches. Due to the prolific nature of GPCRs, Septerna’s diversified portfolio spans multiple therapeutic areas.

<p>Septerna is developing drugs against G-protein coupled receptors (GPCRs). GPCRs are found at the cell membrane and have proven to be the most ‘druggable’ class of proteins. However, many remain ‘undruggable’. Septerna is addressing this problem using their Native Complex platform to design a new era of GPCR-targeted medicines. The platform recapitulates the native structure, function and dynamics of GPCRs, thus enabling structure-based drug design and large-scale screening. Drug hits are further examined with Cryo-EM and optimized through in silico approaches. Due to the prolific nature of GPCRs, Septerna’s diversified portfolio spans multiple therapeutic areas.</p>


Septerna

Company info:

About company:

Jobs: